{"doi":"10.1016/j.neuroscience.2011.05.054","title":"Neuroactive steroids in periphery and cerebrospinal fluid","abstract":null,"journal":"Neuroscience","year":2011,"id":36304,"datarank":2.9850411554660408,"base_score":4.454347296253507,"endowment":4.454347296253507,"self_citation_contribution":0.6681520944380261,"citation_network_contribution":2.316889061028015,"self_endowment_contribution":0.6681520944380261,"citer_contribution":2.316889061028015,"corpus_percentile":null,"corpus_rank":null,"citation_count":85,"citer_count":63,"citers_with_citation_signal":56,"citers_with_endowment":56,"datacite_reuse_total":10,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":128291,"name":"M. Hill","orcid":null,"position":1,"is_corresponding":false},{"id":184183,"name":"Z. Novák","orcid":null,"position":2,"is_corresponding":false},{"id":184184,"name":"J. Chrastina","orcid":null,"position":3,"is_corresponding":false},{"id":184185,"name":"L. Kancheva","orcid":null,"position":4,"is_corresponding":false},{"id":184186,"name":"L. Stárka","orcid":null,"position":5,"is_corresponding":false},{"id":184182,"name":"R. Kancheva","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":4.454347296253507,"endowment":4.454347296253507,"datacite_reuse_total":10,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21641969","pmcid":null,"openalex_id":"https://openalex.org/W2048547196","authors":[],"funders":[],"total_grants":0,"fwci":2.0716,"citation_percentile":0.85808436,"influential_citations":5,"citation_trend":[{"year":2012,"count":5},{"year":2013,"count":11},{"year":2014,"count":4},{"year":2015,"count":5},{"year":2016,"count":7},{"year":2017,"count":5},{"year":2018,"count":4},{"year":2019,"count":9},{"year":2020,"count":5},{"year":2021,"count":8},{"year":2022,"count":2},{"year":2023,"count":4},{"year":2024,"count":13},{"year":2025,"count":2}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0306452211006294?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0306452211006294?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.neuroscience.2011.05.054","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/21641969","host_type":"repository"}],"fields_of_study":["Stress Responses and Cortisol","Estrogen and related hormone effects","Hormonal Regulation and Hypertension","Medicine","Chemistry","Animals","Dehydroepiandrosterone","Humans","Neurotransmitter Agents","Pregnenolone","Rats"],"mesh_terms":["Animals","Dehydroepiandrosterone","Humans","Pregnenolone","Neurotransmitter Agents","Rats"],"keywords":["Pregnenolone","Pregnenolone sulfate","Neuroactive steroid","Dehydroepiandrosterone","Endocrinology","Pregnanolone","Internal medicine","Cerebrospinal fluid","Chemistry","Dehydroepiandrosterone sulfate","Steroid","Blood–brain barrier","Central nervous system","Biology","Medicine","Hormone","Androgen","Receptor","GABAA receptor"],"sdg_mappings":[],"linked_datasets":[{"doi":"10.6084/m9.figshare.14302929.v1","title":"Additional file 1 of Comparison of pregnenolone sulfate, pregnanolone and estradiol levels between patients with menstrually-related migraine and controls: an exploratory study","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.14302929","title":"Additional file 1 of Comparison of pregnenolone sulfate, pregnanolone and estradiol levels between patients with menstrually-related migraine and controls: an exploratory study","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26641777.v1","title":"Additional file 1 of Long read sequencing characterises a novel structural variant, revealing underactive AKR1C1 with overactive AKR1C2 as a possible cause of severe chronic fatigue","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26641777","title":"Additional file 1 of Long read sequencing characterises a novel structural variant, revealing underactive AKR1C1 with overactive AKR1C2 as a possible cause of severe chronic fatigue","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26641783.v1","title":"Additional file 2 of Long read sequencing characterises a novel structural variant, revealing underactive AKR1C1 with overactive AKR1C2 as a possible cause of severe chronic fatigue","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26641783","title":"Additional file 2 of Long read sequencing characterises a novel structural variant, revealing underactive AKR1C1 with overactive AKR1C2 as a possible cause of severe chronic fatigue","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26641786.v1","title":"Additional file 3 of Long read sequencing characterises a novel structural variant, revealing underactive AKR1C1 with overactive AKR1C2 as a possible cause of severe chronic fatigue","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26641786","title":"Additional file 3 of Long read sequencing characterises a novel structural variant, revealing underactive AKR1C1 with overactive AKR1C2 as a possible cause of severe chronic fatigue","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26641789.v1","title":"Additional file 4 of Long read sequencing characterises a novel structural variant, revealing underactive AKR1C1 with overactive AKR1C2 as a possible cause of severe chronic fatigue","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26641789","title":"Additional file 4 of Long read sequencing characterises a novel structural variant, revealing underactive AKR1C1 with overactive AKR1C2 as a possible cause of severe chronic fatigue","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-10T15:30:07.890489Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}